MoonLake Reports Positive Phase 2 AxSpA Results & Secures Up To $400M Non-Dilutive Funding

summarizeSummary

MoonLake Immunotherapeutics announced highly positive Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, demonstrating significant clinical benefit, alongside an amended debt facility providing up to $400 million in non-dilutive future funding.

check_boxKey Events

• Positive Phase 2 AxSpA Trial Results

  Sonelokimab (SLK) demonstrated clinically meaningful and statistically significant benefit in the S-OLARIS Phase 2 trial for axial spondyloarthritis (axSpA), with 81% of patients achieving ASAS40 response at Week 12. This marks the fifth indication with positive data for SLK.

• Secures Up To $400M Non-Dilutive Funding

  The company amended its loan and security agreement, drawing $25 million immediately and establishing access to up to $400 million in additional non-dilutive term loan tranches, contingent on clinical and market capitalization milestones.

• Strong Cash Position & Runway

  MoonLake reported $394.0 million in cash, cash equivalents, and short-term marketable debt securities as of December 31, 2025, with an expected cash runway into the second half of 2027.

• Board Changes Announced

  Simon Sturge resigned from the Board of Directors, effective February 28, 2026. Dr. Jorge Santos da Silva was appointed Interim Chair, and Spike Loy was appointed Lead Independent Director.

auto_awesomeAnalysis

This 8-K filing contains multiple significant positive developments for MoonLake Immunotherapeutics. The topline Phase 2 S-OLARIS trial results for sonelokimab (SLK) in axial spondyloarthritis (axSpA) are a major catalyst, showing clinically meaningful and statistically significant benefits, including 81% of patients achieving ASAS40 response. This marks the fifth indication with positive data for SLK, significantly broadening its potential market. Concurrently, the company amended its loan and security agreement, securing an immediate $25 million draw and establishing access to up to $400 million in additional non-dilutive funding contingent on clinical and market capitalization milestones. This financing provides substantial financial flexibility and extends the cash runway into the second half of 2027, reducing near-term dilution risk. The combination of strong clinical data and robust non-dilutive financing significantly de-risks the company's development pipeline and strengthens its long-term outlook.